Following the first two articles that discussed the treatment of cancer and pain, this third piece will focus on the use of cannabinoids to treat psoriasis and rheumatoid arthritis.
Katharina Zedlacher, PR and communications at BioBloom GmbH, details the recent studies conducted to highlight how cannabinoid CBDa (cannabidiolic acid) increases bioavailability of CBD and its health-promoting properties.
David Shurtleff, PhD, Deputy Director at the National Center for Complementary and Integrative Health, National Institutes of Health (NIH), shares his thoughts on closing gaps in cannabinoid research to make progress in pain management.
Paul McCourt, CEO and Founder of Celtic Wind Crops, outlines his vision for the future when it comes to how growing hemp in the local community can help a global crisis.
In the view of Amanda Feilding, Founder of the Beckley Foundation, “Psychedelics are unique pharmacological compounds that hold the promise of a profound paradigm shift in psychiatry.” Here, we learn about the Psychedelic Renaissance and the importance of drug policy reform.
Farrukh Saleem, Head of Sales & Marketing at Winchester MD, explains why the company is ahead of the curve when it comes to today’s market for CBD products.
Here, OilsBySimpson Founder Kevin Simpson and Clinical Professor, Consultant Physician and Research Director, Filip Krag Knop, explain what we know so far about CBD’s effect on Type 2 diabetes and why running a clinical trial is so important.
